FDA approves Seysara for moderate to severe acne

4 October 2018

US biopharma firm Paratek Pharmaceuticals (Nasdaq: PRTK) was on the receiving end of good news yesterday, as the US Food and Drug Administration approved its acne drug Seysara (sarecycline), adding to the market clearance of its pneumonia and skin infections product Nuzyra (omadacycline), and sending its shares up 8.17% to $9.99 by close of trading.

The FDA has approved Seysara for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

Paratek has exclusively licensed US development and commercialization rights on Seysara for the treatment of acne to Allergan (NYSE: AGN), who has assigned such rights to Spain’s largest drugmaker Almirall (ALM: MC), which will launch the drug in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK